11 recruiting, 7 completed, 3 terminated, 2 active not recruiting. 26 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Recruiting 11, Completed 7, Terminated 3, Active not recruiting 2, Suspended 2, Unknown 1 |
| Phase 2 | 9 | Recruiting 3, Completed 2, Terminated 2, Active not recruiting 1, Unknown 1 |
Follow 5-azacitidine: new trials by email Literature Review of 5-azacitidine trials Research Report on 5-azacitidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-10-30 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-12-01 | 2026-10-29 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2025-07-30 | 2026-09-29 |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-04-25 | 2026-10-20 |
| Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | City of Hope Medical Center | 43 | 2025-01-28 | 2026-07-16 |
| Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 45 | 2024-12-18 | 2026-08-25 |
| Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 30 | 2024-08-22 | 2026-06-30 |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Axatilimab, Azacitidine, Biospecimen Collection - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Uma Borate | 49 | 2024-08-02 | 2026-08-27 |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Revumenib, Venetoclax, Azacitidine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 24 | 2024-04-19 | 2026-10-22 |
| Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse Azacitidine, Chidamide - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 40 | 2022-02-01 | 2026-07-07 |
| Pharmacokinetics, Tolerability and Safety of NEX-18a NEX-18a injection, Azacitidine Injection - Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Completed | Nanexa AB | 2 | 2021-04-27 | 2023-10-17 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS APG-115, 5-azacitidine - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 69 | 2020-12-04 | 2024-02-01 |
| Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | Jennifer Saultz | 51 | 2019-08-16 | 2026-09-24 |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Fludarabine Phosphate - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2019-05-17 | 2025-04-13 |
| Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) GSK3326595, 5-Azacitidine - Neoplasms | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 30 | 2018-10-16 | 2023-02-06 |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Durvalumab, Pralatrexate, Romidepsin - Lymphoma, T-Cell | Phase 1 / Phase 2 | Recruiting | University of Virginia | 148 | 2018-05-30 | 2022-03-31 |
| Nivolumab With Chemotherapy in Refractory MDS Nivolumab, Azacitidine, Fludarabine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | St. Petersburg State Pavlov Medical University | 2 | 2017-05-25 | 2019-04-05 |
| Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Milademetan, AZA - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 | Terminated | Daiichi Sankyo | 74 | 2014-11-25 | 2021-10-11 |
| Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy Birinapant, 5-Azacitidine - Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | TetraLogic Pharmaceuticals | 21 | 2013-06-01 | 2016-04-21 |
Showing 20 of 26. Sign in to see all of them.
Leukemia, Myeloid, Acute (17) · Myelodysplastic Syndromes (10) · Leukemia, Myelomonocytic, Chronic (5) · GATA2 Deficiency (2) · Lymphoma, T-Cell (2) · Recurrence (2) · Anemia, Refractory (1) · Anemia, Refractory, with Excess of Blasts (1) · Enteropathy-Associated T-Cell Lymphoma (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Megakaryoblastic, Acute (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1)
City of Hope Medical Center (4) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (2) · OHSU Knight Cancer Institute (2) · Ascentage Pharma Group Inc. (1) · Daiichi Sankyo (1) · Fred Hutchinson Cancer Center (1) · GlaxoSmithKline (1) · Jennifer Saultz (1) · Nanexa AB (1) · St. Jude Children's Research Hospital (1) · St. Petersburg State Pavlov Medical University (1) · TetraLogic Pharmaceuticals (1) · Uma Borate (1) · University of California, San Diego (1)
United States (23) · Canada (1) · China (1) · Hong Kong (1) · Japan (1) · Russia (1) · Singapore (1) · Sweden (1)
Amanda Blackmon (1) · Annie P Im (1) · Christina Poh (1) · Curtis A Lachowiez (1) · Edward D Ball, MD (1) · Enrica Marchi, M.D., PhD (1) · Francesco Mazziotta, MD, PhD (1) · Gautam Borthakur, MD (1) · Gerald Falchook, MD (1) · Hiroto Inaba, MD, PhD (1) · Jennifer N Saultz (1) · Jennifer N. Saultz, MD (1) · Katherine G Tarlock (1)
PMID 23907406, PMID 39030997, PMID 39290981, PMID 42007254
P30CA033572 (4), N01CM17103 (1), N01CM62204 (1), P01CA018029 (1), P30CA006973 (1), P30CA013330 (1), UM1CA186690 (1)